Skip to search formSkip to main contentSkip to account menu

XELIRI Regimen

Known as: Capecitabine/Irinotecan Regimen, CapIri, XelIri 
A chemotherapy regimen containing capecitabine and irinotecan used in the treatment of colorectal, esophageal and gastric cancer.
National Institutes of Health

Related topics

Related topics

2 relations
Irinotecan hydrochloridecapecitabine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal…
Highly Cited
2018
Highly Cited
2018
A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin
The majority of advanced biliary tract cancer (ABTC) patients will progress after gemcitabine and cisplatin (GP) doublet therapy… 
Highly Cited
2015
Highly Cited
2015
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer
Background:The purpose of this randomised phase III trial was to evaluate whether the addition of simvastatin, a synthetic 3… 
Highly Cited
2013
Highly Cited
2013
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5…
2012
2012
Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: A retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal…
Abstract Background. Metastatic colorectal cancer (CRC) is predominantly a disease of the elderly, therefore the current… 
Highly Cited
2011
Highly Cited
2011
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized…
PURPOSE The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of cetuximab combined with capecitabine… 
Highly Cited
2008
Highly Cited
2008
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
BACKGROUND The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in… 
Highly Cited
2007
Highly Cited
2007
A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer
We sought to evaluate the efficacy and safety data of a combination regimen using weekly irinotecan in combination with… 
Highly Cited
2007
Highly Cited
2007
Capecitabine Plus 3-Weekly Irinotecan (XELIRI Regimen) as First-Line Chemotherapy for Metastatic Colorectal Cancer: Phase II Trial Results
Background:Capecitabine results in superior response rate, improved safety, and improved convenience compared with 5-fluorouracil… 
Highly Cited
2003
Highly Cited
2003
295 Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)